MedTrace Logo

Treatment Patterns & Clinical Outcomes of Palbociclib Combinations in HR+HER2-MBC

NCT04937660 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 185

Last updated 2025-09-22

No results posted yet for this study

Summary

The objective of this non-interventional multicenter study is to provide prospective, observational data on patients initiating treatment with palbociclib combination to contribute to the knowledge of HR+ HER2-metastatic/locally advanced Breast Cancer (BC) disease management, its treatment pattern, clinical outcomes and quality of life (QoL) in the routine clinical practice in Africa and Middle East countries .

Conditions

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-15
Primary Completion
2025-04-29
Completion
2025-04-29

Countries

  • Egypt
  • Jordan
  • Lebanon
  • Qatar
  • Saudi Arabia

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04937660 on ClinicalTrials.gov